Gland Pharma Limited (GLAND.BO)
INR 1762.35
(-0.09%)
INR 1762.35
(-0.09%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 15.03 Billion INR | 4.98% |
| 2022 | 12.08 Billion INR | -26.53% |
| 2021 | 17.34 Billion INR | 20.29% |
| 2020 | 14.37 Billion INR | 33.29% |
| 2019 | 10.94 Billion INR | 38.12% |
| 2018 | 7.72 Billion INR | 33.55% |
| 2017 | 5.84 Billion INR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 2.64 Billion INR | -21.2% |
| 2024 Q2 | 3.56 Billion INR | 12.95% |
| 2023 Q2 | 3.77 Billion INR | 13.8% |
| 2023 FY | - INR | 4.98% |
| 2023 Q4 | 3.58 Billion INR | -8.92% |
| 2023 Q3 | 3.93 Billion INR | 4.39% |
| 2023 Q1 | 3.31 Billion INR | 121.39% |
| 2022 Q4 | 1.49 Billion INR | -57.35% |
| 2022 Q3 | 3.51 Billion INR | -3.14% |
| 2022 Q2 | 3.62 Billion INR | 5.27% |
| 2022 FY | - INR | -26.53% |
| 2022 Q1 | 3.44 Billion INR | -16.38% |
| 2021 Q3 | 3.94 Billion INR | -7.76% |
| 2021 Q1 | 4.98 Billion INR | 33.05% |
| 2021 Q2 | 4.27 Billion INR | -14.12% |
| 2021 FY | - INR | 20.29% |
| 2021 Q4 | 4.11 Billion INR | 4.35% |
| 2020 Q1 | 4.44 Billion INR | 55.96% |
| 2020 Q4 | 3.74 Billion INR | 25.06% |
| 2020 Q3 | 2.99 Billion INR | -5.88% |
| 2020 Q2 | 3.18 Billion INR | -28.48% |
| 2020 FY | - INR | 33.29% |
| 2019 Q3 | 2.37 Billion INR | 0.0% |
| 2019 Q4 | 2.85 Billion INR | 20.28% |
| 2019 Q1 | 2.79 Billion INR | 0.0% |
| 2019 FY | - INR | 38.12% |
| 2018 FY | - INR | 33.55% |
| 2017 FY | - INR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Abbott India Limited | 16.97 Billion INR | 11.456% |
| Cipla Limited | 67.19 Billion INR | 77.628% |
| GlaxoSmithKline Pharmaceuticals Limited | 8.87 Billion INR | -69.425% |
| Kopran Limited | 890.24 Million INR | -1588.645% |
| Marksans Pharma Limited | 4.58 Billion INR | -227.82% |
| NGL Fine-Chem Limited | 678.68 Million INR | -2115.027% |
| Pfizer Limited | 8.23 Billion INR | -82.489% |
| Sanofi India Limited | 8.86 Billion INR | -69.521% |
| SMS Pharmaceuticals Limited | 1.21 Billion INR | -1141.59% |